Serum carcinoembryonic antigen (CEA) is indicated as a valuable prognostic biomarker for recurrence and survival in patients with early non-small cell lung cancer (NSCLC) after curative surgery.
The study involved 18 patients with early-stage NSCLC, measuring their serum CEA levels before and after surgical resection over a follow-up period, revealing that 39% had elevated pre-operative CEA levels.
Results showed that patients with a baseline CEA level above 5.0 ng/ml had significantly poorer disease-free survival compared to those with lower levels, underlining the potential of CEA to identify patients at risk for worse outcomes.